Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options

References

• Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012;2012:460825. PubMed PMID: 22363840; PubMed Central PMCID: PMCPMC3272864.
   PubMedGoogle Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177–189. PubMed PMID: 26092914; PubMed Central PMCID: PMCPMC4515040.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 Aug 15;202(4):473–477. PubMed PMID: 16087714; PubMed Central PMCID: PMCPMC2212860.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol. 2012;3(2):58–73.
   Google Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020 Apr;19(4):298–306. PubMed PMID: 32199095.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013 Jul;19(7):822–824. PubMed PMID: 23836224.
   PubMed Web of Science ®Google Scholar
• Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013 Mar;9(3):154–163. . PubMed PMID: 23419427.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Palace J. Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology. 2018 May 22;90(21):947–948. . PubMed PMID: 29695599.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007 Sep;13(8):968–974. PubMed PMID: 17623727.
   PubMed Web of Science ®Google Scholar
• Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012 Oct;1(4):180–187. PubMed PMID: 24555176; PubMed Central PMCID: PMCPMC3926208.
   PubMed Web of Science ®Google Scholar
• Araki M, Yamamura T. Neuromyelitis optica spectrum disorders: emerging therapies. Clin Exp Neuroimmunol. 2017;8(2):107–116.
   Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar;71(3):324–330. PubMed PMID: 24445513.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Masahiro M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 2014;24(1):67–73.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3701–3706. PubMed PMID: 21321193; PubMed Central PMCID: PMCPMC3048150.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019 Jan;27:412–418. PubMed PMID: 30530071.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14(4):265–277.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002 Jul;125(Pt 7):1450–1461. PubMed PMID: 12076996; PubMed Central PMCID: PMCPMC5444467.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010 Jul;6(7):383–392. PubMed PMID: 20639914.
   PubMed Web of Science ®Google Scholar
• Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008 Oct 27;205(11):2473–2481. PubMed PMID: 18838545; PubMed Central PMCID: PMCPMC2571922.
   PubMed Web of Science ®Google Scholar
• Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci. 2016 Dec;126(12):1051–1060. PubMed PMID: 26954363.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. ‘Spinal amaurosis’ (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. J Neurol. 2014 Feb;261(2):400–404. PubMed PMID: 24366649.
   PubMed Web of Science ®Google Scholar
• Li M, Yan Y. Experimental models of neuromyelitis optica: current status, challenges and future directions. Neurosci Bull. 2015 Dec;31(6):735–744. 10.1007/s12264-015-1552-6. PubMed PMID: 26109280; PubMed Central PMCID: PMCPMC5563723.
   PubMed Web of Science ®Google Scholar
• Graber DJ, Levy M, Kerr D, et al. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008 May 29;5:22. PubMed PMID: 18510734; PubMed Central PMCID: PMCPMC2427020.
   PubMed Web of Science ®Google Scholar
• Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013 Jan;33(1):179–189. PubMed PMID: 22948743.
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Narazaki M, et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019 Apr 16;50(4):1007–1023. PubMed PMID: 30995492.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010 May;22(5):347–352. PubMed PMID: 20410258*
   PubMed Web of Science ®Google Scholar
• Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994 Jan 7;263(5143):92–95. PubMed PMID: 8272873.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994 Jun 1;300(Pt 2):281–290. PubMed PMID: 8002928; PubMed Central PMCID: PMCPMC1138158.
   PubMed Web of Science ®Google Scholar
• Garbers C, Heink S, Korn T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018 Jun;17(6):395–412. PubMed PMID: 29725131.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010 Dec;16(12):1443–1452. PubMed PMID: 20739337.
   PubMed Web of Science ®Google Scholar
• Heink S, Yogev N, Garbers C, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017 Jan;18(1):74–85. PubMed PMID: 27893700; PubMed Central PMCID: PMCPMC5164931.
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010 Jul;40(7):1830–1835. PubMed PMID: 20583029.
   PubMed Web of Science ®Google Scholar
• Mathur AN, Chang HC, Zisoulis DG, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol. 2007 Apr 15;178(8):4901–4907. PubMed PMID: 17404271.
   PubMed Web of Science ®Google Scholar
• Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099–12104. PubMed PMID: 17623780; PubMed Central PMCID: PMCPMC1924582.
   PubMed Web of Science ®Google Scholar
• Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008 May 8;453(7192):236–240. PubMed PMID: 18368049; PubMed Central PMCID: PMCPMC2597437.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006 May 11;441(7090):235–238. PubMed PMID: 16648838.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006 May 11;441(7090):231–234. PubMed PMID: 16648837.
   PubMed Web of Science ®Google Scholar
• Mendel I, Katz A, Kozak N, et al. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol. 1998 May;28(5):1727–1737. PubMed PMID: 9603480.
   PubMed Web of Science ®Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005 May;128(Pt 5):988–1002. PubMed PMID: 15743872.
   PubMedGoogle Scholar
• Wu A, Zhong X, Wang H, et al. Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis. Can J Neurol Sci. 2012 Nov;39(6):813–820. PubMed PMID: 23041403.
   PubMed Web of Science ®Google Scholar
• Xu W, Li R, Dai Y, et al. IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2013 Aug 15;261(1–2):87–91. PubMed PMID: 23726764.
   PubMed Web of Science ®Google Scholar
• Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov;69(11):1482–1487. PubMed PMID: 22926050; PubMed Central PMCID: PMCPMC3561507.
   PubMedGoogle Scholar
• Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica–prevalence, pathogenesis and therapy. Nat Rev Neurol. 2014 Sep;10(9):529–536. PubMed PMID: 25072195.
   PubMed Web of Science ®Google Scholar
• Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013 Jul;23(4):827–831. PubMed PMID: 22782533; PubMed Central PMCID: PMCPMC3713263.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014 Apr 15;82(15):1302–1306. PubMed PMID: 24634453; PubMed Central PMCID: PMCPMC4001188.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013 Mar 1;70(3):394–397. PubMed PMID: 23358868.
   PubMed Web of Science ®Google Scholar
• Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019 Dec 30;39:101920. PubMed PMID: 31918241.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015 Jul;72(7):756–763. PubMed PMID: 25985228.
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010 Nov;28(11):1203–1207. PubMed PMID: 20953198.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010 May;23(5):385–392. PubMed PMID: 20159773.
   PubMed Web of Science ®Google Scholar
• Katagiri R, Ishihara-Hattori K, Frings W, et al. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey. Birth Defects Res. 2017 Jul 3;109(11):843–856. PubMed PMID: 28504465.
   PubMedGoogle Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114–2124. PubMed PMID: 31774956.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg B, Bennett JL, et al. Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study. J Neurol Sci. 2019;405. DOI:10.1016/j.jns.2019.10.1108.
   Web of Science ®Google Scholar
• Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017 Apr 1;56(4):541–549. PubMed PMID: 28013198; PubMed Central PMCID: PMCPMC5410975.
   PubMed Web of Science ®Google Scholar
• Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017 Jul;13(7):399–409. PubMed PMID: 28615731.
   PubMed Web of Science ®Google Scholar
• Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 Apr;78(4):456–464. PubMed PMID: 30679153.
   PubMed Web of Science ®Google Scholar